AVILEX PHARMA ApS: Financial statements 2024
CVR: 34896828
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
AVILEX PHARMA ApS (CVR 34896828) has filed annual accounts for 2024. In 2024, the company reported a net result of DKK -4,428,000 compared with DKK -6,756,000 the year before. Equity in the 2024 report amounted to DKK -6,267,000. The company had 2 employees in the financial year.
- Profit/Loss
- DKK -4,428,000
- Equity
- DKK -6,267,000
- Total Assets
- DKK 21,559,000
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | - | -4.4 mio. | -6.3 mio. | 2 |
| 2023 | 0 | 0 | -6.8 mio. | -1.8 mio. | 2 |
| 2022 | 45.5 mio. | 45.5 mio. | 28.6 mio. | 4.9 mio. | 2 |
| 2021 | - | - | -6.6 mio. | -25.3 mio. | 2 |
| 2020 | - | -3.1 mio. | -3 mio. | -18.6 mio. | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
AVILEX PHARMA ApS has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -6,756,000.
About AVILEX PHARMA ApS
AVILEX PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristian Strømgaard. The board consists of Raymond George Hill (chair), Camilla Petrycer Hansen, Jonathan Mark Treherne and Kristian Strømgaard. The company's owners include Novo Holdings A/S, MIKAEL SØNDERGÅRD THOMSEN ApS and KRISTIAN STRØMGAARD HOLDING ApS. The company has 4 employees (2025). In 2025, the company reported a net result of DKK -4,530,000 compared with DKK -4,428,000 the year before. Equity in the 2025 report amounted to DKK -10,797,000.